BeOne Medicines combines 36% revenue growth, a Piotroski F-Score of 9/9, a wide economic moat, and a Rule of 40 score of 51 with strong analyst conviction (54% upside consensus), but the stock is in a confirmed falling knife pattern with RSI at 22, a death cross in place, and BRUKINSA product concentration risk from a single revenue driver.
Thesis pillars
- Brukinsa Concentration Growth Engine→Stable
- Wide Moat Compounder Quality→Stable
- Falling Knife Technical Setup→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
BeOne Medicines Ltd. (ONC) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait for pullback to $346.19. Weak momentum — blocks BUY_NOW at $355.00. Engine's entry $346.19 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum.
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total... Read more
Wait for pullback to $346.19. Weak momentum — blocks BUY_NOW at $355.00. Engine's entry $346.19 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Score 6.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 1d<=7d. Suitability: speculative.
Recent developments
updated Oct 28, 2026Recent Developments — BeOne Medicines Ltd.
Latest news
- NEWS What BeOne Medicines Stock Trial Win Means For Shareholders - Simply Wall St — Simply Wall St Oct 28, 2026 positive
- NEWS ONC 261120 270.00P (ONC261120P270000) Stock Options Chain | Quotes & News - Moomoo — Moomoo Oct 21, 2026 neutral
- NEWS BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock - MarketBeat — MarketBeat Sep 30, 2026 negative
- NEWS BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock - marketbeat.com — marketbeat.com Sep 30, 2026 negative
- NEWS BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033 - tipranks.com — tipranks.com Sep 23, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-04T11:34:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRUKINSA10-K Item 1: 'total global revenue of approximately $5.3 billion ... BRUKINSA generated $3.9 billion in sales in 2025'
- MEDIUMGeographicChina10-K Item 1A: 'which could have a material adverse effect on our business, financial condition and results of operations in China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $346.19. Weak momentum — blocks BUY_NOW at $355.00. Engine's entry $346.19 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Target $393.81 (+10.9%), stop $330.23 (−7.5%), A.R:R 1.7:1. Score 6.4/10, moderate confidence.
Take-profit target: $393.81 (+10.9% upside). Target $393.81 (+10.9%), stop $330.23 (−7.5%), A.R:R 1.7:1. Stop-loss: $330.23.
Concentration risk — Product: BRUKINSA; Negative momentum.
BeOne Medicines Ltd. trades at a P/E of 63.5 (forward 34.0). TrendMatrix value score: 4.9/10. Verdict: Buy (Wait for Entry).
11 analysts rate ONC, with a consensus score of 4.2/5. 27 analysts publish price targets averaging $438.
What does BeOne Medicines Ltd. do?BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK...
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total revenue in 2025, with BRUKINSA contributing $3.9 billion in sales, and employs nearly 12,000 people across research, clinical, and commercial operations.